Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...
Neurodegenerative diseases pose a serious threat to public health, with an increasing impact among the elderly population.
Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...
Heartland Real Estate Partners founder and chairman David Husman committed $20 million to Nova Southeastern University to ...
A renowned Israeli TV journalist who lost his ability to speak clearly because of ALS is returning to the air using ...
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...
About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...
The voice of Israeli journalist Moshe Nussbaum has been revived using artificial intelligence after he was diagnosed with ALS ...
A research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other neurodegenerative disorders such as ...
When a renowned Israeli TV journalist lost his ability to speak clearly because of ALS, he thought his career might be over.
Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces it has entered a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback